Transgene SA TNG

Strasbourg, France, October 1, 2026, 5:45 pm CET — Transgene (Euronext Paris: TNG), a biotech company developing myvac®, an individualized neoantigen therapeutic vaccines (INTV) platform designed to prevent cancer recurrence together with a portfolio of virus-based candidates, today announced that its management team will meet institutional investors during the upcoming edition of Investor Access Event (by Investor Access), on October 6, 2026, in Paris. Organized by Investor Access, these events

2026 Half-Year Results and Business Update myvac® – Expanding potential across solid tumors through viral vector, AI driven neoantigen selection, and scalable cell-line manufacturing TG4050 – First Individualized Neoantigen Therapeutic Vaccine (INTV) from the myvac® platform advancing in resected HNSCC1 Randomized Phase 1 data published in Nature Communications; Sustained 100% disease-free survival (DFS) after more than 3 years of follow-up, showing durable clinical outcomes and potential to pre

Strasbourg (France), Berlin (Germany), September 8, 2026, 7:30 a.m. CEST – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and ProBioGen, a leading contract development and manufacturing organization (CDMO) in biologics, vaccines and viral vectors, today announce that the companies have broadened the scope of their existing collaboration. Transgene’s additional license agreement for ProBioGen’s AGE1.CR.pIX® sus

TG4050 as a single agent has the potential to prevent recurrence in head and neck cancer Peer-reviewed publication in Nature Communications highlights the Phase 1 clinical and translational findings, including durable neoantigen-specific T cell responses Together, the long-term clinical and translational data further strengthen confidence in Transgene’s individualized neoantigen therapeutic vaccine approach and myvac® platform Strasbourg, France & Tokyo, Japan, September 2, 2026, 6:00 p.m. CET –

Strasbourg, July 7, 2026 – 06:00 pm CET Under the liquidity contract entrusted by Transgene to Natixis Oddo BHF SCA, as of June 30, 2026, the following resources were managed through the liquidity account: 391,029 shares€ 81,393.60 During the first half of 2026, a total of the following trades were executed: Purchases453,960 shares€ 373,2451,101 market transactionsSales367,410 shares€ 307,064767 market transactions It is recalled that: as of December 31, 2025, the following resources were manage

Combining cutting-edge proprietary technologies and enhanced manufacturing, TG4070 is positioned as a novel vaccine relevant to multiple tumor types TG4070, the second candidate from the myvac® platform: Full internalized AI-driven capabilities with SNIPER, a novel neoantigen prediction toolScalable cell-line manufacturing designed to support faster vaccine supply and broader platform deploymentNew randomized Phase 1 trial in combination with immune checkpoint inhibitor in adjuvant NSCLC1 – Pati

Strasbourg, France, May 4, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that the documentation related to the Combined General Meeting (ordinary and extraordinary sessions) of Transgene’s shareholders is available. The notice of meeting, comprising the agenda and the draft resolutions, was published in the Bulletin des Annonces Légales Obligatoires (BALO) no. 44 of April 13, 2

Enrolment completed in Phase 2 part of head and neck cancer clinical trial (TG4050) – Topline data expected by the end of Q1 2028 as per planPhase 1 data from TG4050 in head and neck cancer published on medRxivLicense agreement signed with NEC Bio to advance clinical development of TG4050 in head and neck cancerFinancial visibility until early 2028 Strasbourg, France, April 29, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunoth

Two-year disease-free survival from evaluable Phase 2 patients expected by the end of Q1 2028. Strasbourg, France, April 13, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced the completion of patient randomization in the Phase 2 part of the Phase 1/2 clinical trial evaluating TG4050, an individualized neoantigen therapeutic vaccine (INTV) developed from Transgene’s myvac® pl

Strasbourg, France, April 7, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will meet institutional investors during the upcoming editions of: Investor Access Event (by Allinvest Securities), on April 9, 2026, in Paris (France);Life Sciences Conference (by Van Lanschot Kempen), on April 16, 2026, in Amsterdam (Netherlands). Next financial communica

Strasbourg, France & Schiphol, Netherlands, April 2, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Bio B.V. (“NEC”), a wholly owned subsidiary of NEC Corporation (TSE: 6701), a leader in IT, network and AI technologies, announce the signing of a license agreement to advance the clinical development of TG4050, an individualized neoantigen therapeutic vaccine (INTV) in the adjuvant

Strasbourg, France, March 26, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced a 30-minute oral presentation on TG4050, the Company’s Individualized Neoantigen Therapeutic Vaccine (INTV) at the World Vaccine Congress (WVC), taking place from March 31 to April 2, 2026, in Washington, D.C., USA. The presentation will be held on April 1st. The presentation will highlight findin

Transgene SA (STU:TGNA) strengthens its financial position and showcases promising clinical advancements, setting the stage for future growth.

2025 Full-year results and business update Transgene Continues Progressto Reshape Early-Stage Cancer Treatmentthrough Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility Until Early 2028 TG4050, Transgene’s first INTV, demonstrated durable clinical outcomes in resected head and neck squamous cell carcinoma (HNSCC) and potential to prevent cancer relapseRandomization of Phase 2 patients nearly completed -Disease-free survival1 from evaluable patients in the Phase